Short Interest in Johnson & Johnson (NYSE:JNJ) Expands By 6.7%

Johnson & Johnson (NYSE:JNJGet Free Report) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 15,840,000 shares, an increase of 6.7% from the February 29th total of 14,850,000 shares. Currently, 0.7% of the company’s shares are short sold. Based on an average trading volume of 6,900,000 shares, the days-to-cover ratio is currently 2.3 days.

Insider Activity at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Institutional Trading of Johnson & Johnson

A number of hedge funds have recently bought and sold shares of JNJ. State Street Corp lifted its holdings in shares of Johnson & Johnson by 1.1% during the 2nd quarter. State Street Corp now owns 141,833,756 shares of the company’s stock worth $23,476,323,000 after acquiring an additional 1,568,633 shares during the period. Moneta Group Investment Advisors LLC lifted its holdings in shares of Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after acquiring an additional 54,326,454 shares during the period. Morgan Stanley lifted its holdings in shares of Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after acquiring an additional 4,521,062 shares during the period. Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $4,609,399,000. Finally, Wellington Management Group LLP lifted its holdings in shares of Johnson & Johnson by 16.4% during the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock worth $3,764,852,000 after acquiring an additional 3,391,657 shares during the period. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on JNJ. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Wells Fargo & Company lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. Raymond James upped their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Seven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $177.31.

Get Our Latest Stock Analysis on JNJ

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $154.27 on Thursday. Johnson & Johnson has a 1 year low of $144.95 and a 1 year high of $175.97. The firm’s fifty day simple moving average is $158.35 and its 200 day simple moving average is $156.49. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $371.76 billion, a PE ratio of 11.17, a PEG ratio of 2.65 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The business had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same period last year, the business posted $2.35 EPS. Johnson & Johnson’s revenue was down 9.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current year.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Read More

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.